Table 8: Results at Week 26 in a Trial Comparing TRESIBA to Insulin Detemir in Pediatric Patients 1 Year of Age and Older with Type 1 Diabetes Mellitus Receiving Insulin Aspart at Mealtimes The change from baseline to end of treatment visit in HbA1c was analyzed using ANOVA with missing data imputed by multiple imputation carrying forward the baseline value and adding the error term, with treatment, region, sex, and age group as fixed factors, and baseline HbA1c as covariate
Specifically, the ELIXA (lixisenatide) trial studied patients with T2DM who had recent acute coronary syndrome and found that the addition of lixisenatide to conventional therapy did not result in a significant difference in cardiovascular endpoints relative to placebo (Table 1) [56]
The compounded telehealth route exists because that price gap is real and significant
Here is my honest clinical perspective, based on more than 25 years of practice and treating over 1,500 patients here at The Lamkin Clinic in Edmond
According to a meta-analysis, oral semaglutide (14 mg once-daily) resulted in a sustained weight loss compared to placebo (2.99 kg